ARTICLE | Company News

Celgene, Boston Children's Hospital cancer news

January 13, 2014 8:00 AM UTC

In July 2013, the hospital filed suit against Celgene in the U.S. District Court for the District of Massachusetts claiming a breach of contract. On or about Dec. 31, 2002, the hospital had granted Celgene an exclusive license to IP covering angiogenesis inhibitors in exchange for specified payments and royalties on revenues from sales of amino thalidomide products and marketed drugs Revlimid lenalidomide for multiple myeloma (MM) and myelodysplastic syndromes (MDS) and Pomalyst pomalidomide for MM...